The FDA on June 22, 2017 granted regular approval to RITUXAN HYCELA® for adult patients with Follicular lymphoma, Diffuse Large B-Cell Lymphoma, and Chronic Lymphocytic Leukemia. RITUXAN HYCELA® is a product of Genentech Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
